A Potential New Therapy for Dermatomyositis: Findings from the VALOR Study
Автор: dermatomyositis_com
Загружено: 2025-11-10
Просмотров: 190847
Описание:
Dr. Michelle Min, Director of Rheumatologic Dermatology at UC Irvine Health, shares results from the VALOR study, which tested an investigational, once-daily oral medication called brepocitinib for adults with dermatomyositis (DM).
In this year-long study, patients taking brepocitinib experienced meaningful improvements in muscle strength, skin symptoms, and overall function compared to placebo. Many were even able to reduce or stop steroid use — a major step forward for long-term care.
This is the first time a medicine has shown such strong results in a year-long, placebo-controlled trial for dermatomyositis — a rare autoimmune disease that affects both the muscles and the skin.
Learn more about progress in dermatomyositis research at dermatomyositis.com.
Timestamps:
00:00 – Introduction: Dr. Michelle Min, UC Irvine
00:23 – What is brepocitinib, a new dermatomyositis medicine?
00:50 – Encouraging VALOR study results
01:23 – VALOR study summary
01:48 – About brepocitinib and what’s next
#Dermatomyositis #DermatomyositisTreatment #DermatomyositisResearch #DermatomyositisCommunity #ClinicalTrial #AutoimmuneDisease #HopeInScience
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
